Galectin's GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis
Research done in partnership with
The exploratory, open-label, Phase 2a trial enrolled five adult patients with moderate-to-severe plaque psoriasis (PASI ≥ 12 and BSA ≥ 10%) to undergo infusions of 8 mg/kg of GR-MD-02 every other week for 24 weeks (13 infusions total). The primary endpoint of the trial was a reduction in PASI score of 75% (PASI-75) with secondary endpoints measuring adverse events and achieving PASI-50. One patient exceeded the primary endpoint with an 80% reduction in PASI 30 days after their last infusion, while the other four patients reached PASI-50 by their 10th infusion. All five patients completed the treatment phase of the study with no serious adverse events.
"We are pleased by the results of our 24-week psoriasis trial demonstrating the safety and efficacy of GR-MD-02 in patients with moderate to severe plaque psoriasis," said
Psoriasis, which manifests most often as plaque psoriasis, is a chronic, relapsing, inflammatory skin disorder. Although plaque psoriasis is rarely life threatening, it often is refractory to treatment. According to the
GR-MD-02 is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of fatty liver disease and fibrosis. Galectin-3 plays a major role in diseases that involve scarring of organs including fibrotic disorders of the liver, lung, kidney, heart and vascular system. The drug binds to galectin proteins and disrupts their function. Preclinical data in animals have shown that GR-MD-02 has robust treatment effects in reversing liver fibrosis and cirrhosis.
Jack Callicutt, Chief Financial Officer (678) 620-3186 firstname.lastname@example.org
News Provided by Acquire Media